Antifungal Drug Market Trend, Share, Growth, Size Analysis and Forecast 2030

Antifungal Drug Market

Antifungal Drug Market- By Drug Type (Echinocandins, Azoles, Polyenes, and Allylamines), By Indication (Aspergillosis, Dermatophytosis, and Candidiasis), By Dosage Form (Powder, Ointments, and Tablets), and By Distribution Channel (Hospital Pharmacies and Retail Pharmacies & Drug Stores): Global Industry Perspective, Comprehensive Analysis, And Forecast, 2022–2028

Category: Pharmaceutical Report Format : PDF Pages: 190 Report Code: ZMR-534 Published Date: Mar-2022 Status : Published

The global antifungal drug market size earned $15.1 billion in 2021 and is expected to generate $20.23 billion by 2028, growing at a CAGR of 3.7%.

The global Antifungal Drug Market accrued earnings worth approximately 15.1 (USD Billion) in 2021 and is predicted to gain revenue of about 20.23 (USD Billion) by 2028, is set to record a CAGR of nearly 3.7% over the period from 2022 to 2028. The study provides assessment and analysis of the Antifungal Drug Market on a global & regional level. It offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2021 along with a forecast from 2022 to 2028 based on revenue (USD Billion).

COVID Impact Analysis On Antifungal Drug Market

Outbreak of pandemic has restricted expansion of size of antifungal market and is likely to continue even in next few years. Reportedly, rapid spread of SARS-CoV-2 virus has not only hampered economy of nation, but also severely affected various business including pharmaceutical businesses like antifungal drug sales. With increase in lockdown period for restricting spread of pandemic and strict government measures limiting movement of persons from one place to another has affected supply chain activities, thereby posing a threat to sale of antifungal drugs.  

Antifungal Drug Market: Outlook

Invasive fungal infections are a key cause of mortality in immune-compromised patients and this has proved to be economic burden on healthcare sector across globe. As per NCBI, these infections have caused nearly 2 million fatalities each year. Moreover, recent antifungal drugs have proved to be less clinically efficient and new antifungal agents along with new combination regimens as well as new drug formulations for improving patient care will drive market trends. Furthermore, antifungal drugs eradicate pathogens from hosts with minimal side-effects. In addition to this, launching of novel antifungal medicines such as echinocandins and second-generation triazoles in last few years has favorably influenced managing of invasive mycoses in a way that drug toxicity has become less vital factor in drug treatment of fungal infections.

Additionally, antifungal drugs are also referred to as antimycotic drugs and it is a fungistatic utilized for treating mycosis including ringworm, athlete’s foot, cryptococcal meningitis, and candidiasis. Anti-fungal drugs can be bifurcated into three types, namely, azoles that inhibit ergosterol synthesis, polyenes which interacts with fungal membrane sterols physio-chemically, and 5-flurocystosine that obstruct macromolecular synthesis.

Global Antifungal Drug MarketRequest Free Sample

Antifungal Drug Market: Growth Drivers

Occurrence of fungal infections in immune-compromised patients such as AIDS, cancer patients, and individuals affected due to autoimmune disorders will offer new growth avenues for antifungal drug industry. Surge in use of nanotechnology in formulation of advanced antifungal medicines will impel expansion of antifungal drug industry. A prominent increase in nosocomial infections in patients will spearhead demand for antifungal drugs in healthcare sector. Nonetheless, use of conventional medicines can hinder growth of antifungal drug industry.

Furthermore, increase in awareness about fungal infections and surge in drug demand for countering chronic fungal diseases will steer penetration of antifungal drugs in healthcare sector. This will spur increase in size of antifungal drug market. Innovations in drug development and huge investment of drug research activities will prompt expansion of antifungal drug market.

Antifungal Drug Market: Regional Landscape

North America To Account Substantially Towards Regional Market Share By 2028

Growth of antifungal drug industry in North America over forecast timespan is owing to surge in use of novel antifungal drugs for treating fungal infections. For instance, in December 2020, the U.S. FDA approved application of Scynexis Inc. for its drug ibrexafungerp that has ability for treating vaginal yeast infection. Apart from this, rise in funding of research work related to new antifungal drugs will expand scope of antifungal drug market in years to come.

Report Scope:

 

Competitive Insights

Key players have majorly influenced growth of antifungal drug market and will continue to do so even in next couple of years. They are Asperqillus, Abbott Laboratories, Alternaria, Enzon Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Glaxosmithkline plc, Bayer Healthcare, Novartis AG, Sanofi S.A., Kramer Laboratories, and Gilead Sciences, Inc.

The global Antifungal Drug Market is segmented as follows:

By Drug Type

  • Echinocandins

  • Azoles
  • Polyenes
  • Allylamines

By Indication

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis

 By Dosage Form

  • Powder
  • Ointments
  • Tablets

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

FrequentlyAsked Questions

Occurrence of fungal infections in immune-compromised patients such as AIDS, cancer patients, and individuals affected due to autoimmune disorders will offer new growth avenues for antifungal drug industry.   

According to Zion market research report, The global Antifungal Drug Market accrued earnings worth approximately 15.1 (USD Billion) in 2021 and is predicted to gain revenue of about 20.23 (USD Billion) by 2028, is set to record a CAGR of nearly 3.7% over the period from 2022 to 2028.

North America will contribute lucratively towards the global market earnings over the projected timeline. The regional market surge is subject to surge in use of novel antifungal drugs for treating fungal infections in sub-continent.     

The key market participants leveraging business sphere include Asperqillus, Abbott Laboratories, Alternaria, Enzon Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Glaxosmithkline plc, Bayer Healthcare, Novartis AG, Sanofi S.A., Kramer Laboratories, and Gilead Sciences, Inc.

 

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed